Houston-based Bellicum Pharmaceuticals Inc. continues to rearrange its C-suite.
Bellicum (Nasdaq: BLCM), a pharmaceutical company focusing on the treatment of specific types of cancer, named Dr. Gregory Naeve as its chief business officer, according to a release. His position is effective Aug. 21.
Naeve's appointment occurs after Annemarie Moseley announced in May plans to step down as the company’s COO and executive vice president of clinical development. In January, the company named Rick Fair…
Houston-based Bellicum Pharmaceuticals Inc. continues to rearrange its C-suite.
Bellicum (Nasdaq: BLCM), a pharmaceutical company focusing on the treatment of specific types of cancer, named Dr. Gregory Naeve as its chief business officer, according to a release. His position is effective Aug. 21.
Naeve's appointment occurs after Annemarie Moseley announced in May plans to step down as the company’s COO and executive vice president of clinical development. In January, the company named Rick Fair…